Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7657795 | 0.89 | MAPT (0.47) | KMT2AMEN1NOTUMKDM4EALDH1A1 | |
| SCHEMBL295953 | 0.84 | NOTUM (0.61) | KMT2AMEN1NOTUMKDM4EALDH1A1 | |
| SCHEMBL3112806 | 0.82 | MAPT (0.57) | KMT2AMEN1NOTUMKDM4EALDH1A1 | |
| SCHEMBL13485837 | 0.81 | MAPT (0.60) | KMT2AMEN1NOTUMKDM4EALDH1A1 | |
| SCHEMBL4341894 | 0.80 | NOTUM (0.78) | KMT2AMEN1NOTUMKDM4EALDH1A1 | |
| SCHEMBL8203335 | 0.78 | MAPT (0.54) | KMT2AMEN1NOTUMKDM4EALDH1A1 | |
| SCHEMBL1661109 | 0.78 | MAPT (0.50) | KMT2AMEN1NOTUMKDM4EALDH1A1 | |
| SCHEMBL7657790 | 0.76 | NOTUM (0.51) | KMT2AMEN1NOTUMKDM4EALDH1A1 | |
| SCHEMBL598184 | 0.75 | NOTUM (0.64) | KMT2AMEN1NOTUMKDM4EALDH1A1 | |
| SCHEMBL14154815 | 0.74 | MAPT (0.51) | KMT2AMEN1NOTUMKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9169281-B2 | Mononuclear metal complex, hydrogenation reduction catalyst, dehydrogenation catalyst, method for producing hydrogenation reduction product, method for producing hydrogen (H2), and method for producing dehydrogenation reaction product | OSAKA UNIVERSITY (JP) | 2015-10-27 | — | — | US | disclosed |
| US-8765779-B2 | Tricyclic derivatives and their pharmaceutical use and compositions | CEPHALON, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2543675-A1 | MONONUCLEAR METAL COMPLEX, HYDROGENATION REDUCTION CATALYST, DEHYDROGENATION CATALYST, METHOD FOR PRODUCING HYDROGENATION REDUCTION PRODUCT, METHOD FOR PRODUCING HYDROGEN (H2), AND METHOD FOR PRODUCING DEHYDROGENATION REACTION PRODUCT | Osaka University (JP) | 2013-01-09 | — | — | EP | disclosed |
| US-20120321550-A1 | MONONUCLEAR METAL COMPLEX, HYDROGENATION REDUCTION CATALYST, DEHYDROGENATION CATALYST, METHOD FOR PRODUCING HYDROGENATION REDUCTION PRODUCT, METHOD FOR PRODUCING HYDROGEN (H2), AND METHOD FOR PRODUCING DEHYDROGENATION REACTION | OSAKA UNIVERSITY (JP) | 2012-12-20 | — | — | US | disclosed |
| US-20120295882-A1 | Tricyclic Derivatives and Their Pharmaceutical Use and Compositions | CEPHALON, INC. (US) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295882-A1 | Tricyclic Derivatives and Their Pharmaceutical Use and Compositions | CYP3A43, CYP3A7, CYP2C19 | KMT2A 4588/4885MEN1 1341/4885NOTUM 1358/4885 |
| US-20120321550-A1 | MONONUCLEAR METAL COMPLEX, HYDROGENATION REDUCTION CATALYST, DEHYDROGENATION CATALYST, METHOD FOR PRODUCING HYDROGENATION REDUCTION PRODUCT, METHOD FOR PRODUCING HYDROGEN (H2), AND METHOD FOR PRODUCING DEHYDROGENATION REACTION | MON2, HRH3, AP2M1 | KMT2A 594/4885MEN1 361/4885NOTUM 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.